nach oben

Drugs & Aging

Erschienen in:

01.09.2005 | Review Article

Male Osteoporosis

New Trends in Diagnosis and Therapy

verfasst von: Dr Hosam K. Kamel

Erschienen in: Drugs & Aging | Ausgabe 9/2005

Einloggen, um Zugang zu erhalten

Abstract

Osteoporosis is a common condition in men affecting approximately 2 million males in the US. Compared with women, osteoporosis develops later in life and the incidence of osteoporosis-related fractures is lower in men. The morbidity and mortality associated with osteoporotic fractures are much greater in men compared with women, and secondary causes of osteoporosis are more frequently (in approximately 50% of cases) identified in men compared with women with osteoporosis. Excessive alcohol consumption, glucocorticoid excess and hypogonadism are the most commonly identified causes. Primary osteoporosis in men has been linked to changes in sex steroid secretion, the growth hormone-insulin-like growth factor-1 (GH-IGF-1) axis and the vitamin D-parathyroid hormone (PTH) 25-hydroxyvitamin D [25(OH)D]-PTH system.

Diagnosing osteoporosis in men is complicated by an ongoing debate on whether to use sex-specific reference values for bone mineral density (BMD) or female reference values. The International Society for Clinical Densitometry recommended using a T score of −2.5 or less of male reference values to diagnose osteoporosis in men who are ≥65 years of age. However, this definition is yet to be validated in terms of fracture incidence and prevalence.

Ensuring adequate calcium and vitamin D intake is the cornerstone of any regimen aimed at preventing or treating osteoporosis in men. Bisphosphonates are currently the therapy of choice for treatment of male osteoporosis. A short course of parathyroid hormone (1–34) [teriparatide] may be indicated for men with very low BMD or in those in whom bisphosphonate therapy is unsuccessful. The use of testosterone-replacement therapy for the prevention and treatment of male osteoporosis remains controversial but likely to benefit osteoporotic men with evident hypogonadism.

Looker AC, Orwoll ES, Johnston Jr CC, et al. Prevalence of low femoral bone density in older US adults from NHANES III. J Bone Miner Res 1997; 12: 1761–8PubMedCrossRef

Diamond TH. Pharmacotherapy of osteoporosis in men. Expert Opin Pharmacother 2005; 6(1): 45–58PubMedCrossRef

Poor G, Atkinson EJ, Lawallen DG, et al. Age-related hip fracture in men: clinical spectrum and short-term outcomes. Osteoporos Int 1995; 5: 419–26PubMedCrossRef

Boonen S, Vanderschueren D. Bone loss and osteoporotic fracture occurrence in aging men. In: Lunenfeld B, Gooren L, editors. Textbook of men’s health. New York: Parthenon Publishing Group, 2002: 455–62

Orwoll ES. Osteoporosis in men. Endocr Rev 1995; 19: 87–116

Turner RT. Skeletal response to alcohol. Alcohol Clin Exp Res 2000; 24(11): 1693–701PubMedCrossRef

Yuan Z, Dawson N, Cooper GS, et al. Effects of alcohol-related disease on hip fracture and mortality: retrospective cohort study of hospitalized Medicare beneficiaries. Am J Public Health 2001; 91(7): 1089–93PubMedCrossRef

Compston J. Glucocorticoid-induced osteoporosis. Horm Res 2003; 60Suppl. 3: 77–9PubMedCrossRef

O’Brien CA, Jia D, Plotkin LI, et al. Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. Endocrinology 2004 Apr; 145(4): 1835–41PubMedCrossRef

10.

Van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 2002; 13(10): 777–87PubMedCrossRef

11.

Stanley HL, Schimt BP, Poses RM, et al. Does hypogonadism contribute to the occurrence of a minimal trauma hip fracture in elderly men? J Am Geriatr Soc 1991; 39: 766–71PubMed

12.

McElduff A, Wilkinson M, Ward P, et al. Forearm mineral content in normal men: relationship to weight, height and plasma testosterone concentrations. Bone 1988; 9: 281–3PubMedCrossRef

13.

Ongphiphadhanakul B, Rajatanavin R, Chailurkit L, et al. Serum testosterone and its relation to bone mineral density and body composition in normal males. Clin Endocrinol 1995; 43: 727–33CrossRef

14.

Finkelstein JS, Klibanski A, Neer RM, et al. Increases in bone density during treatment of men with idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab 1989; 69: 776–83PubMedCrossRef

15.

Orwell ES, Stribraska EB, Ramsey EE, et al. Androgen receptors in osteoblast-like cells. Calcif Tissue Int 1991; 49: 183–7CrossRef

16.

Masuyama A, Ouchi Y, Sato F, et al. Characteristics of steroid hormone receptors in cultured LC3T3-E1 osteoblastic cells and effects of steroid hormone receptors on cell proliferation. Calcif Tissue Int 1992; 51: 376–81PubMedCrossRef

17.

Mozuno Y, Hosoi T, Inoue S, et al. Immunocytochemical identification of androgen receptor in mouse osteoclast-like multinucleated cells. Calcif Tissue Int 1994; 54: 325–9CrossRef

18.

Vanderschueren D, Bouillon R. Androgens and bone. Calcif Tissue Int 1995; 56: 341–6PubMedCrossRef

19.

Kamel HK, Perry HM, Morley JE. Hormone replacement therapy and fractures in older adults. J Am Geriatr Soc 2001; 49: 179–87PubMedCrossRef

20.

Preston DM, Torrens JI, Harding P, et al. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss. Prostate Cancer Prostatic Dis 2002; 5(4): 304–10PubMedCrossRef

21.

Melton III LJ, Alothman KI, Khosla S, et al. Fracture risk following bilateral orchiectomy. J Urol 2003; 169(5): 1747–50PubMedCrossRef

22.

Seeman E. Osteoporosis in men: epidemiology, pathophysiology, and treatment possibilities Am J Med 1993; 95(5A): 22S–28SPubMedCrossRef

23.

Kamel HK. Osteoporosis and aging: etiology and current diagnostic strategies. Ann Long Term Care 1998; 6(11): 352–7

24.

Khosla S, Melton III LJ, Atkinson EJ, et al. Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen. J Clin Endocrinol Metab 1998; 83: 2266–74PubMedCrossRef

25.

Reed BY, Zerwekh JE, Sakhaee K, et al. Serum IGF 1 is low and correlated with osteoblastic surface in idiopathic osteoporosis. J Bone Miner Res 1995; 10: 1218–24PubMedCrossRef

26.

Ljunghall S, Johansson AG, Burman P, et al. Low plasma levels of insulin-like growth factor 1 (IGF-1) in male patients with idiopathic osteoporosis. J Intern Med 1992; 232: 59–64PubMedCrossRef

27.

Kurland ES, Chan FKW, Rosen CJ, et al. Normal growth hormone secretory reserve in men with idiopathic osteoporosis and reduced circulating levels of insulin-like growth factor-1. J Clin Endocrinol Metab 1998; 83: 1–4CrossRef

28.

Rosen CJ, Kurland ES, Vereault D, et al. An association between serum IGF-1 and a simple sequence repeat in the IGF-1 gene: implications for genetic studies of bone mineral density. J Clin Endocrinol Metab 1998; 83: 2286–90PubMedCrossRef

29.

Khosla S, Atkinson EJ, Dunstan CR, et al. Effect of estrogen versus testosterone on circulating osteoprotegerin and other cytokine levels in normal elderly men. J Clin Endocrinol Metab 2002; 87(4): 1550–4PubMedCrossRef

30.

Khosla S, Melton III LJ, Riggs BL. Clinical review 144: estrogen and the male skeleton. J Clin Endocrinol Metab 2002; 87(4): 1443–50PubMedCrossRef

31.

Smith EP, Boyd J, Frank GR, et al. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med 1994; 331: 1056–61PubMedCrossRef

32.

Morishima A, Grumbach MM, Simpson ER, et al. Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J Clin Endocrinol Metab 1995; 80: 3689–98PubMedCrossRef

33.

Bilezikkian JP, Morishima A, Bell J, et al. Increased bone mass as a result of estrogen therapy in a man with aromatase deficiency. N Engl J Med 1998; 339: 599–603CrossRef

34.

Colon-Emeric C, Yballe L, Sloane R, et al. Expert physician recommendations and current practice patterns for evaluating and treating men with osteoporotic hip fractures. J Am Geriatr Soc 2000; 48(10): 1261–3PubMed

35.

National Osteoporosis Foundation. Physician’s guide to prevention and treatment of osteoporosis. Washington, DC: National Osteoporosis Foundation, 2003

36.

Eastell R, Boyle IT, Compston J, et al. Management of male osteoporosis: report of the UK Consensus Group. QJM 1998; 91(2): 71–92PubMedCrossRef

37.

Report of a WHO Study Group. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. World Health Organ Tech Rep Ser 1994; 843: 3–5

38.

Writing Group for the ISCD Position Development Conference. Diagnosis of osteoporosis in men, premenopausal women, and children. J Clin Densitom 2004 Spring; 7(1): 17–26CrossRef

39.

Kanis JA, Seeman E, Johnell O, et al. The perspective of the International Osteoporosis Foundation on the official positions of the International Society for Clinical Densitometry. J Clin Densitom 2005; 8(2): 145–7PubMedCrossRef

40.

Benito M, Gomberg B, Wehrli FW, et al. Deterioration of trabecular architecture in hypogonadal men. J Clin Endocrinol Metab 2003; 88: 1497–502PubMedCrossRef

41.

Jackson JA, Kleerekoper M, Parfitt AM, et al. Bone histomorphometry in hypogonadal and eugonadal men with spinal osteoporosis. J Clin Endocrinol Metab 1987; 65: 53–8PubMedCrossRef

42.

Kelepouris N, Harper KD, Gannon F, et al. Severe osteoporosis in men. Ann Intern Med 1995; 123: 452–60PubMed

43.

Orwoll ES, Oviatt SK, McClung MR, et al. The rate of bone mineral loss in normal men and the effects of calcium and cholecalciferol supplementation. Ann Intern Med 1990; 112: 29–34PubMed

44.

Dawson-Hughes B, Harris SS, Krall EA, et al. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 1997; 337: 670–6PubMedCrossRef

45.

NIH Consensus conference. Optimal calcium intake: NIH consensus development panel on optimal calcium intake. JAMA 1994; 272: 1942–8CrossRef

46.

Walden O. The relationship of dietary and supplemental calcium intake to bone loss and osteoporosis. J Am Diet Assoc 1989; 89(3): 397–400PubMed

47.

Orwoll ES, Ettinger M, Weiss S, et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med 2000; 343: 604–10PubMedCrossRef

48.

Kamel HK, Hajjar RR. Osteoporosis for the home care physician. Part 2: management. J Am Med Dir Assoc 2004; 5(4): 259–62PubMedCrossRef

49.

Kamel HK. Underutilization of calcium and vitamin D supplements in an academic long term care facility. J Am Med Dir Assoc 2004; 5: 98–100PubMedCrossRef

50.

Bauer E, Aub JC, Albright F. Studies of calcium and phosphorous metabolism: V. A study of the bone trabeculae as a readily available reserve of calcium. J Exp Med 1929; 49: 145–62PubMedCrossRef

51.

Selye H. On the stimulation of new bone-formation with parathyroid extracts and irradiated ergosterol. Endocrinology 1932; 16: 547–58CrossRef

52.

Kurland ES, Cosman F, McMahon DJ, et al. Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. J Clin Endocrinol Metab 2000; 85(9): 3069–76PubMedCrossRef

53.

Orwoll ES, Scheele WH, Paul S, et al. The effect of teriparatide [human parathyroid hormone (1–34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 2003; 18(1): 9–17PubMedCrossRef

54.

Finkelstein JS, Hayes A, Hunzelman JL, et al. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 2003; 349(13): 1216–26PubMedCrossRef

55.

Tenover JS. Effects of testosterone supplementation in the aging male. J Clin Endocrinol Metab 1992; 75: 1092–8PubMedCrossRef

56.

Morley JE, Perry III HM, Kaiser FE, et al. Effects of testosterone replacement therapy in old hypogonadal males: a preliminary study. J Am Geriatr Soc 1993; 41: 149–52PubMed

57.

Katznelson L, Finkelstein JS, Schoenfeld DA, et al. Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. J Clin Endocrinol Metab 1996; 81: 4358–90PubMedCrossRef

58.

Snyder PJ, Peachey H, Hannoush P, et al. Effect of testosterone treatment on bone mineral study in men over 65 years of age. J Clin Endocrinol Metab 1999; 84(6): 1966–72PubMedCrossRef

59.

Behre HM, Kliesch S, Leifke E, et al. Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. J Clin Endocrinol Metab 1997; 82: 2386–90PubMedCrossRef

60.

Reid IR, Wattie DJ, Evans MC, et al. Testosterone therapy in glucocorticoid-treated men. Arch Intern Med 1996; 156: 1173–7PubMedCrossRef

61.

Sih R, Morley JE, Kaiser FE, et al. Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial. J Clin Endocrinol Metab 1997; 82: 1661–7PubMedCrossRef

62.

Tenover JS. Effects of testosterone supplementation in the aging male. J Clin Endocrinol Metab 1992; 75: 1092–8PubMedCrossRef

63.

Morley JE, Kaiser FE, Sih R, et al. Testosterone and frailty. Clin Geriatr Med 1997; 13(4): 685–94PubMed

64.

Kamel HK, Bida A, Montagnini M. Secondary prevention of hip fractures in veterans: can we do better? J Am Geriatr Soc 2004; 52(4): 647–8PubMedCrossRef

65.

Meryn S. Undertreatment of osteoporosis in men [abstract]. Arch Intern Med 2005; 165(2): 241PubMedCrossRef

Titel: Male Osteoporosis
New Trends in Diagnosis and Therapy
verfasst von: Dr Hosam K. Kamel
Publikationsdatum: 01.09.2005
Verlag: Springer International Publishing
Erschienen in: Drugs & Aging / Ausgabe 9/2005
Print ISSN: 1170-229X
Elektronische ISSN: 1179-1969
DOI: https://doi.org/10.2165/00002512-200522090-00003

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2005

Botulinum Toxin Treatment of Oesophageal Achalasia in the Old Old and Oldest Old

Effects of Inhaled Corticosteroids on Mortality and Hospitalisation in Elderly Asthma and Chronic Obstructive Pulmonary Disease Patients

Effect of Creatinine Clearance on Patterns of Toxicity in Older Patients Receiving Adjuvant Chemotherapy for Breast Cancer

Use of Psychotropic Drugs in Elderly Nursing Home Residents with and without Dementia in Helsinki, Finland

Alternatives to Levodopa in the Initial Treatment of Early Parkinson’s Disease